Business Wire

Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Share

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda®, as an anti-inflammatory drug for early-stage COVID-19 treatments. A recent preclinical trial, conducted in partnership with Australia’s Hudson Institute of Medical Research (Hudson Institute), has identified that idronoxil inhibits the enzyme, TANK-binding kinase 1 (TBK1), an action that potentially dampens the inflammatory response causing the progression of COVID-19 disease from mild-to-severe, but not compromising the body’s ability to fight the virus.

These preclinical findings support preliminary top-line positive results the company shared earlier from its NOXCOVID Phase I clinical trial, which tested the suitability of idronoxil (Veyonda) as an effective anti-inflammatory in patients hospitalized with moderate COVID-19 disease. One particular relevance of TBK1 as a drug target is its role in responding to infections from RNA viruses including the respiratory RNA viruses - coronaviruses, influenza virus and respiratory syncytial virus.

Associate Professor Michael Gantier, Head of the Nucleic Acids and Innate Immunity Laboratory at Hudson Institute said: “TBK1 is a point of convergence of many inflammatory pathways, and a target under significant investigation by several big pharmaceutical companies. Our latest findings, which are being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases where TBK1 facilitates aberrant inflammation. Critically, TBK1 also directly controls production of interferon-beta, a cytokine associated with long-COVID symptoms. This suggests that idronoxil may not only be useful to prevent progression of COVID-19 patients from mild to severe disease, but also may decrease the risk of long-lasting post-infectious symptoms, seen in up to half of COVID-19 patients.”

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).

Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions — a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies, and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of U.S. biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lindsey Langemeier
SCORR Marketing
+1 402-405-4269
lindsey@scorrmarketing.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

XY Labs / XYO Network Announces Record Profits for the First Half of 2021 With 2x Growth29.9.2021 01:56:00 CEST | Press release

The XYO Network (Coinbase: $XYO), the geospatial blockchain network, announced today a recent record 2x growth as well as profitability for the first half of 2021. XY Labs generated net income of $3,841,615 in the first half of 2021 through a plethora of disclosed and undisclosed partnerships vs a loss of $1,967,793 in the first half of 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006178/en/ XYO stated that the number of nodes for the XYO Network had doubled in size over the last three months, noting a promising outlook for the remaining 2021 year and emphasizing a strong recovery from the global lull caused by COVID-19. The company’s announcement shines a light on the constant financial struggle for many crypto-projects, whose main assets like crypto tokens and currencies experience extreme volatility on the decentralized exchanges they trade on. Arie Trouw, one of the project’s founders and CEO of the parent

Spotahome Partners With Homeppl to Offer Tenant Guarantee Solution to Its Landlords Following Rise in Demand for Medium-term Lets29.9.2021 00:01:00 CEST | Press release

Spotahome, the Spanish-based residential platform which manages 200,000 properties in 29 different countries across Europe, has signed an agreement with UK-based tenant due diligence and guarantee firm Homeppl to provide its landlords with a tenant referencing and guarantor service for its medium and long-term lets. With the world opening-up and embracing a post-pandemic life, demand for both medium and long-term rentals has tripled, so being able to approve tenants quickly is imperative. But the risk of tenant fraud remains high, so it is vital that landlords have secure tenant referencing systems in place. Homeppl’s solution combines fraud detection tests, behavioural analysis and financial algorithms, as well as Open Banking data, to assess the true transactional ability of consumers from all over Europe. It has a 0% default rate, and Homeppl is so confident in its referencing solution that it also offers guarantid - a service where it acts as a guarantor for tenants it approves - g

Lunaphore Spatial Biology Technologies to be Featured at Spatial Biology US Conference28.9.2021 21:00:00 CEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced several presentations featuring the company’s spatial biology technologies at the Spatial Biology US conference taking place virtually September 27 – 30, 2021. Presentations will feature COMET™, Lunaphore’s all-in-one staining and imaging platform for high throughput, hyperplex immunofluorescence, and LabSat®, the company’s compact and open automated tissue staining instrument for immunohistochemistry and multiplex immunofluorescence. PRESENTATION DETAILS How to Optimize a Hyper-Plex Immunostaining Panel in a Fast and Robust Manner Date and time: September 29, 2021 / 4:30 – 5:00 PM ET Speaker: Saska Brajkovic, Head of Application Development, Lunaphore Spatial Proteomics: A Journey to Adopt New Highly Multiplexed Immunohistochemistry Technologies1 Date and time: September 29, 2021 / 2:20 – 2:40 PM ET Speaker: Alexander Klimowicz, Senior Principal Scientist, Boeh

Andersen Global Expands Footprint in Asia; Adds Presence in Four Countries28.9.2021 20:48:00 CEST | Press release

Andersen Global extends its global platform’s eastern coverage through a Collaboration Agreement with tax advisory firm BoardRoom Business Solutions Pte. Ltd., adding 14 locations across Singapore, Malaysia, China and Hong Kong. Founded in 1968, BoardRoom offers a full suite of tax, finance, payroll and corporate secretarial services, providing business solutions and corporate advisory to clients including Fortune 500 multinationals, public companies and privately-owned enterprises. The firm is led by Group CEO Kim Teo and Managing Director of BBS Chester Leong, and operates with 19 Partners and over 800 professionals. “We are pleased to be collaborating with like-minded professionals who invest in their people and promote stewardship to ensure clients receive best-in-class solutions,” Kim said. “Our combined expertise and synergy afford us the opportunity to deliver integrated, independent services in a seamless manner globally.” “BoardRoom provides broad coverage and establishes a st

SKEMA and EADA Create a Double-Degree BBA in Barcelona28.9.2021 19:46:00 CEST | Press release

SKEMA Business School and EADA Business School have signed an agreement to launch a new joint double-degree BBA programme "SKEMA X EADA Global BBA" in Barcelona, where EADA operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006004/en/ Official signing of the partnership between SKEMA and EADA on 20 September 2021 from SKEMA Business School’s Grand Paris Campus. From left to right: Patrice Houdayer, Director of Programmes, International and Student Life, Koke Pursals, Chairman of the Board of Directors of the EADA Foundation, Alice Guilhon, SKEMA’s Dean & Executive President, and Jordi Diaz, EADA’s Dean. (Photo: Business Wire) Through this alliance, SKEMA intends to develop a new European base from EADA's Barcelona campus. EADA will benefit from the presence of SKEMA’s campuses in five continents. At the same time, the two schools also aim to open this new four-year post-baccalaureate programme to candidates from

Zayed Sustainability Prize Announces 30 Finalists During Jury Meeting28.9.2021 19:42:00 CEST | Press release

The Zayed Sustainability Prize, the UAE’s pioneering award for recognising sustainable solutions and humanitarianism, held its Jury meeting to elect winners for its current 2022 cycle, who will be announced during the Prize’s Awards Ceremony at the 2022 Abu Dhabi Sustainability Week (ADSW), this January. A total of 30 finalists were confirmed and are now vying for 10 awards, across the five categories of Health, Food, Energy, Water, and Global High Schools. This year, the Prize received a remarkable 4,000 applications, marking a significant 68.5% increase in entries compared to the previous cycle, while attracting submissions from a record 151 countries, representing over three quarters of the world’s nations. The Prize Jury, comprising former heads of state, government ministers and international business figures, convened through a virtual meeting to review shortlisted submissions identified by the Prize’s Selection Committee in August. In his remarks, H.E. Dr. Sultan bin Ahmed Al Ja

MMIT/Evaluate Acquire Panalgo to Bring Speed and Trust to Pharma Analytics and Decision-Making28.9.2021 17:45:00 CEST | Press release

Managed Markets Insight & Technology (MMIT) and Evaluate, (a Welsh, Carson, Anderson & Stowe and Hg portfolio company)—which joined forces last month to become a $1.6 billion global pharma commercial intelligence provider—announced the acquisition of Panalgo, a premier healthcare data analytics company that serves many of the largest biopharmaceutical, medical device and contract research organizations around the globe. “MMIT/Evaluate and Panalgo share a vision of generating evidence and insights faster, all to help patients get timely access to lifesaving therapies,” said MMIT CEO Mike Gallup. “The addition of Panalgo fits perfectly into our strategy of building a best-in-breed technology- and services-driven healthcare business servicing pharma, biotech and beyond.” With this acquisition, MMIT/Evaluate aim to transform the process of bringing drugs to market. By incorporating Panalgo’s flagship Instant Health Data (IHD) software, MMIT/Evaluate will offer customers an end-to-end comme